Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | Jin Medical International Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
16.07. | Jin Medical International Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
16.07. | Jin Medical International Ltd.: Jin Medical Launches Production at Plant No. 3, Accelerating Global Delivery from the Chuzhou Manufacturing Facility | 1 | GlobeNewswire (USA) | ||
JIN MEDICAL INTERNATIONAL Aktie jetzt für 0€ handeln | |||||
24.06. | Jin Medical International ernennt Dr. James Jiayuan Tong zum unabhängigen Direktor | 6 | Investing.com Deutsch | ||
24.06. | Jin Medical International Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
17.06. | Jin Medical International Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
06.05. | Jin Medical International Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
06.05. | Jin Medical International Ltd. - Nasdaq Minimum Bid Price Non-Compliance | 52 | GlobeNewswire (Europe) | Changzhou City, China, May 06, 2025 (GLOBE NEWSWIRE) -- Jin Medical International Ltd. (NASDAQ: ZJYL) (the "Company") today announced that on May 2, 2025, it received a deficiency letter (the "Notice")... ► Artikel lesen | |
25.04. | Jin Medical International Ltd. - 6-K, Report of foreign issuer | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SERNOVA BIOTHERAPEUTICS | 0,118 | +0,85 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes | LONDON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics ("Sernova") (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) today announced a Collaborative Research Agreement with Eledon Pharmaceuticals... ► Artikel lesen | |
PLUS THERAPEUTICS | 0,483 | 0,00 % | Plus Therapeutics Inc.: Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ in Leptomeningeal Metastases | REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures RNA sequencing and circulating tumor cell reduction consistent with tumor cell death No dose limiting... ► Artikel lesen | |
ATOSSA THERAPEUTICS | 0,641 | +0,63 % | Atossa Therapeutics Inc: Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update | FDA Provides Positive Feedback, Clears Path for Atossa to File IND for (Z)-Endoxifen in Metastatic Breast Cancer; FDA Indicates No Additional Toxicity Studies Required
Strong... ► Artikel lesen | |
PING AN HEALTHCARE | 1,732 | +1,64 % | Ping An Healthcare and Technology Company Limited: Ping An Good Doctor (1833.HK) Reports Solid Interim Results with Steady Revenue and Profit Growth | HONG KONG, Aug. 20, 2025 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited (the "Company"; Stock Code: 1833.HK) announced its interim results for the six months ended June... ► Artikel lesen | |
MOUNTAIN VALLEY MD | 0,011 | -13,64 % | Mountain Valley MD Holdings Inc: Mountain Valley appoints Batchelor as director | ||
CO-DIAGNOSTICS | 0,254 | +4,96 % | Co-Diagnostics, Inc. Reports Second Quarter 2025 Financial Results | SALT LAKE CITY, Aug. 14, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development... ► Artikel lesen | |
CYTOSORBENTS | 0,790 | +0,89 % | CytoSorbents Corporation: CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR | FDA appeal decision found no issues with DrugSorb-ATR device safety but upheld the De Novo denial, and proposes a potential path forward for market authorization... ► Artikel lesen | |
VERU | 3,550 | +9,57 % | Veru Announces Novel Modified-Release Oral Formulation for Enobosarm | ||
AMBU | 12,830 | +0,23 % | Ambu A/S: Interim Report For Q2 2024/25 And The Half-year | 7.5.2025 07:00:01 CEST | Ambu A/S |
Half Year financial report
In the second quarter of the 2024/25 financial year, Ambu delivered 11.7% organic revenue growth and a 14.4% EBIT margin before special... ► Artikel lesen | |
TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update | Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in ChinaGranted orphan drug designation from the European Medicines... ► Artikel lesen | |
VOLITIONRX | 0,675 | 0,00 % | VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update | Conference call to discuss financial and operational results scheduled for Friday, August 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., Aug. 14, 2025 /PRNewswire/ -- VolitionRx... ► Artikel lesen | |
FRESENIUS | 47,060 | +0,90 % | Fresenius: Starkes Kaufsignal! | Der Trading-Tipp des Tages ist diesmal Fresenius. Die Aktie hat in dieser Woche ein neues Kaufsignal generiert. Zuletzt gab es fundamental bereits gute Nachrichten. Die Quartalszahlen waren stark. Fresenius... ► Artikel lesen | |
FRESENIUS MEDICAL CARE | 43,270 | +0,60 % | DZ BANK stuft FMC FRESENIUS MEDICAL CARE AG auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat die Einstufung für Fresenius Medical Care (FMC) nach Zahlen zum zweiten Quartal auf "Kaufen" mit einem fairen Wert von 60 Euro belassen. Der Dialysekonzern... ► Artikel lesen | |
SIEMENS HEALTHINEERS | 48,150 | +0,99 % | Aktienmarkt: Siemens Healthineers-Aktie tritt auf der Stelle (46,41 €) | Wenig Kursbewegung zur Stunde bei der Aktie von Siemens Healthineers . Der jüngste Kurs betrug 46,41 Euro. Eine gerine Verbilligung von 0,15 Prozent zeigt die Kurstafel für der Anteilsschein von Siemens... ► Artikel lesen | |
UNITEDHEALTH | 257,40 | +0,10 % | Bitcoin überholt Google! Folgt Apple als Nächstes? AMD, UnitedHealth im Check | Der Bitcoin sorgt wieder einmal für Furore, die Kryptowährung erreichte ein neues Allzeithoch. Samir Boyardan und Andreas Wolf von HeavytraderZ analysieren die Gründe und zeigen, wie es jetzt weitergeht.... ► Artikel lesen |